Tag: GlobeNewswire

        PRESS RELEASE

                Paris, 6^th October 2026

Annual results at the end of June 2026

Revenue growth and disciplined efficiency drive
stronger operational profitability
Capital Markets Day on 17^th September: Ramsay Santé outlined its new strategic roadmap “Connecting Care 2030”, integrated healthcare model and long-term value creation framework

• Group Revenue up 3.3% to €5.4bn (+2.3% LFL) sustained by: (i) a recognized quality offering driving volumes in France with a further development of day hospitalisation, (ii) strong fundamentals in the Nordics, with positive price indexation, favourable currency effects, and the first semester of contribution from St. Göran new contract.
• Group EBITDA up 2.6% at €638m (11.9% margin, up versus last year excluding temporary French revenue guarantee), with sustained and disciplined operating cost control, performance and efficiency offsetting public funding constraints and French revenue guarantee anticipated shortfall
• Net cash flow from operating activities at €525m, down €169m year-on-year due to working capital returning to a more normalized position at the end of June 2026 than the previous year.
• Net financial debt at €3,585m, including €1,639m of restated (pre-IFRS16) net debt.
• Pre-IFRS16 restated net leverage stable at 4.7x (vs. 4.7x as of June 2025) supported by higher profitability, achieved despite working capital reverting to a more normalised level.
• Successful refinancing of senior debt in July 2026, enhancing the group’s financial flexibility, and providing a platform for long term strategic ambitions.

From Yes We Care 2025 to 2030 strategy: a pan-European integrated Healthcare platform
ready to enter its next phase of growth

• Yes We Care 2025 has enabled Ramsay Santé to consolidate an integrated European platform caring for 13 million patients across five countries, from prevention and primary care to mental health, rehabilitation and acute care.
• A key role in expanding access to care – Nearly 690,000 emergency department visits handled in France, with medical, surgical and obstetric admissions up 2.5%.
• A continuously expanding care platform – Three new mental health day centres and 11 additional imaging units in France since July 2025.
• Stronger positions across Europe – A new contract for St. Göran Hospital in Sweden, with a duration of up to 12 years and an estimated total value of €4.8 billion.
  • Excellence recognized – Quality certification scores 10 points above national average in France, reflecting superior medical outcomes and patient experience and Patient record Net Promoter Score of 73% at Group level
  • A growing reputation – Group awareness reaches 85% in France, 75% in Norway, 71% in Sweden, strengthening trust and visibility across markets.

At its Capital Markets Day on 17th September, Ramsay Santé unveiled “Connecting Care 2030” to drive the next phase of profitable growth and create long term value for all stakeholders

• “Connecting Care 2030”, Ramsay Santé Group’s new strategic roadmap, leverages the transformation achieved through the successful execution of previous plan “Yes We Care 25”
• Building on these achievements, Connecting Care 2030 puts medical excellence and patient-centered care at the heart of Ramsay Santé Group’s next phase of development and is built on five clear strategic pillars:
  • Strengthen the integrated and accessible Healthcare offering,
  • Embrace the digital transformation of Healthcare delivery,
  • Ensure active portfolio and contract management,
  • Continue to focus on cost initiatives measures,
  • Accelerate additional profitable growth through new revenue streams.
• The new plan offers a clear path towards sustained topline growth and gradual margin improvement underpinned by a disciplined capital investment policy to strengthen its platform, support innovation and invest in the future of Healthcare:
  • FY2029: Revenue growth¹ c.3.0% per annum² and EBITDA margin gradually improving
  • Continued deleveraging, targeting Net debt³/EBITDA (pre-IFRS) <4.0x

Pascal Roché, Chief Executive Officer of Ramsay Santé, said:

“The year ended 30^th June 2026 confirms the strength of our business model, based on a truly integrated care offering and anchored in medical excellence. Revenue increased by 3.3% to €5.4 billion, while EBITDA rose by 2.6% to €638 million, driven by strong activity, the quality of our care offering and continued operational discipline. Over the past five years, Yes We Care 2025 has profoundly transformed Ramsay Santé. We have built an integrated European platform operating across five countries and caring for 13 million patients every year, from prevention and primary care to mental health, rehabilitation and acute care.

At our Capital Markets Day on 17^th September 2026, we have presented our next strategic roadmap, “Connecting Care 2030”, operational priorities and medium-term financial ambitions. We will further integrate care pathways, accelerate innovation and strengthen operational excellence. Our goal is to connect more of the patient journey, deepen our position in attractive areas of care, use digital and AI to improve both access and productivity, actively manage our portfolio and contracts, and create new sources of profitable growth.

This long-term roadmap will translate into tangible action our purpose “Improving health through constant innovation” and our commitments as a Mission-driven company. Supported by the talent and commitment of its employees and medical partners, the Group has a strong foundation to deliver an integrated healthcare model and a long-term value creation framework.”

The Board of Directors approved the consolidated accounts as of the end of June 2026 at its meeting held on                                6^th October 2026. The auditors’ certification report on the consolidated accounts has been issued. In line with the Company’s position in recent years, it will not be proposed to the next Annual General Meeting of Shareholders to pay a dividend for the year ending 30th June 2026. The consolidated financial statements and reports will be available to the public when the company’s universal registration document is published at the end of October 2026.

KPIs – June 2026

P&L – in € millions	From July 1, 2025 to June 30, 2026	From July 1, 2024 to June 30, 2025	Variation
Revenue	5,381.1	5,207.9(1)	+3.3% (LFL +2.3%)
EBITDA	637.7	621.4	2.6%
EBITDA as a % of revenue	11.9%	11.9%	+0.0 pts
Net result (Group share)	(48.3)	(54.1)	+5,8
Operating Cash Flow	524.7	693.7	-169,0
Net Leverage (pre-IFRS)	4,7x	4,7x	0,0x

^{(1) Adjusted of a reclassification of €–34.1m on revenue and +€34.1m on purchased consumables, with no impact on EBITDA.}

Significant events of the period

New chapter for Ramsay Santé in connection with Ramsay Health Care’s proposal to distribute its shareholding in Ramsay Santé to its shareholders: On February 20^th, 2026, Ramsay Santé publicly noted the announcement by its shareholder, Ramsay Health Care Limited (RHC), of a proposed plan to distribute its 52.79% shareholding in Ramsay Santé to RHC’s own shareholders. Commenting on the announcement, CEO Pascal Roché stated that the proposal would open a new chapter for Ramsay Santé, adding that the Group’s solid resources and positions allow it to approach this step with confidence and serenity, while remaining fully committed to delivering high-quality, innovative and accessible care in close collaboration with healthcare professionals and the regions. This proposal would be implemented through a scheme of arrangement under Australian law, which would be subject to the approval of RHC’s Board of Directors and its shareholders, as well as the necessary court and regulatory authorisations. Ramsay Santé continues to carefully assess all the legal, financial and operational implications that may arise from this transaction and will ensure that its capital structure remains stable in the context of a potential increase in the free float. According to information released by RHC, the proposal could be implemented during Q4 2026, subject to the required approvals. In accordance with applicable regulations, Ramsay Santé has performed the information and consultation process with its employee representative bodies. The Group will keep the market informed of any significant developments, in accordance with its ongoing disclosure obligations (please notably refer to subsequent events of the period regarding debt refinancing, CMD, and CDI application).

Delivering high performance in Sweden – Capio enters into new St. Göran’s contract in January 2026:
Capio has transitioned into a new contract to provide care at St. Göran’s Hospital on behalf of the Stockholm region on 5^th January 2026. As previously announced, Capio was awarded this new contract on 22^nd October 2024, for a term of at least eight years, with the right for Region Stockholm to extend the agreement for a maximum of four years for a contract value, calculated over 12 years, amounting to EUR 4.8 billion (SEK 55 billion) with better price conditions. The transition has taken place according to plan.

Through disciplined portfolio management, the Group continues to optimize its asset mix, selectively monetising real estate and non-core assets to strengthen liquidity and support long-term investment in healthcare services

Leveraging real estate portfolio with optimized efficiency: Sale and lease-back of the real estate of 4 French facilities in May 2026: Ramsay Santé has sold the real estate of 4 of its French facilities at the end of May 2026 to La Française REM for net proceeds of €45m (net of stamp duty) and leased those assets back on 12-year fixed term leases. Ramsay Santé continues to operate those 3 mental health and one MSO clinics, which are strongly anchored in their respective local catchment areas. Further investments will be made to enhance the properties and align them with evolving energy transition requirements. This transaction unlocks additional liquidity from a limited portion of the Group’s real estate portfolio to support its core healthcare business, while retaining long-term operational control of the facilities. It also reflects the quality and attractiveness of the Group’s assets and the strength of the underlying operation.

HP Jean Mermoz real estate refinancing: On 30^th July 2025, the Group refinanced the real estate finance lease that had reached maturity at the Jean Mermoz facility in France (Lyon) through the payment of the €31m option available and concomitantly has drawn €65m under a new 12-year mortgage loan secured by the property, hence increasing liquidity by €34m.

Disposal of non-core, non-hospital businesses in France: In June 2026, Ramsay Santé sold two separate non-strategic, non-hospitals businesses: (i) Baya Hotel in Capbreton in France sold to Parallel Hospitality and (ii) patient transport activities in the Lyon area (France) taken over by Groupe Hunault (specialised in ambulance transportation). Net proceeds from the sale and the P&L contribution of those activities are not material to the group. Please note that the patient transport activity was classified as discontinued operations in the group’s financial statement since the year ended 30 June 2025.

Significant subsequent events since the period

Ramsay Santé successfully completes its senior debt refinancing: On 22^nd July, 2026, Ramsay Santé announced the closing of its €1.75 billion refinancing launched on 24^th June comprising a €1.55 billion Term Loan B and a €200 million revolving credit facility. The new Term Loan B was successfully priced at E+350bps / 99.0 OID, anchored by both new and existing lenders. This refinancing will enhance the group’s financial flexibility, extending senior debt maturities from 2031 to 2033 and simplify its capital structure by refinancing the €100 million Euro PP notes maturing in 2028 and 2029. It also pre-emptively preserves the continuity and stability of its financing arrangements, with a change of control provision structured to accommodate the contemplated distribution of RHC’s 52.79% shareholding in Ramay Santé to RHC shareholders by way of an in-specie distribution. Such refinancing provides Ramsay Santé and all its stakeholders with a long-term financing framework and strengthen the group’s capacity to pursue its long-term ambitions.

Ramsay Santé has held a Capital Markets Day on 17^th September 2026: Ramsay Santé hosted a Capital Markets Day on 17^th September 2026 in Paris, at which senior management presented to investors and research analysts the group’s next strategic roadmap “Connecting Care 2030”, operational priorities and medium-term financial ambitions. This event gave the opportunity to showcase the group’s renewed ambition to pursue profitable growth while continuing to deliver excellent patient care, supported by a new and broader shareholding and driven by the talent and commitment of all its employees and medical partners. Presentation materials are available at www.ramsaysante.eu.

Application for listing as CDIs tradeable on the ASX: Ramsay Santé has applied for a foreign exempt listing on the ASX, and to put in place arrangements so that RHC shareholders may hold their interest in Ramsay Santé through CDIs, which would be tradeable on the ASX, subject to all applicable approvals. A CDI would provide the equivalent economic exposure and voting entitlement as an ordinary listed share in Ramsay Santé.

HP Dijon-Bourgogne real estate refinancing: On 20^th July 2026, the Group refinanced the real estate finance lease that had reached maturity at its Dijon-Bourgogne facility in France (Dijon) through the payment of the €13m option available, and simultaneously added on 31^st July 2026 a new tranche of security trust (“Fiducie”) debt amounting to €67.5m for a 10-year tenure, hence increasing liquidity by €54m whilst diversifying its funding sources and maturity profiles at attractive conditions. Arranged by Natixis, this new Fiducie financing was supported by a pool of lenders composed of various entities of Groupe BPCE, La Banque Postale and BPI France.
Comments on the annual accounts

Activity and revenue

Ramsay Santé Group reported consolidated revenues of €5,381m, up 3.3% on a reported basis. Adjusted for changes in the consolidation scope and at constant currency exchange rates, revenues were up 2.3% (LFL).

France total revenue growth has reached 1.9% and is essentially organic driven. France total admissions in our hospitals rose year-on-year reflecting sustained patient need for healthcare and the capacity of the group’s facilities to provide more quality care services in a competitive landscape: +2.5% in MSO (medicine, surgery and obstetrics) patient stays admissions driven by ambulatory care. Our French facilities managed approximately 690,000 emergency presentations this year confirming their major role in delivering on public service missions. The growth in admissions was curtailed by the impact from a 3-day strike by medical practitioners in January 2026, however partly offset by catch-up of volumes in the following months. This growth of admissions combined with (i) a limited pricing benefit from the +0.5% MSO tariff increase effective from March 2025, followed by no MSO tariff increase from January 2026 and (ii) the cancellation of the CICE coefficient not applied to January and February 2025 last year and now embedded in the tariff base adding c. €9m, has been partly offset by (iii) a negative mix effect from higher growth of day patient volumes vs decreasing inpatient stays (iv) as well as c. €8m impact of price cuts on imaging procedures.

French total revenue growth also reflects the opening of 3 mental health day facilities in the period and the installation of 11 new imaging equipment since July 2025.

Nordic countries total reported revenue grew by +6.5% benefitting from €51m (or 3.2%) favourable foreign exchange rate fluctuation (appreciation of SEK vs EUR versus last year). Organic revenue growth in the Nordics was +3.1% on a like-for-like basis and at constant exchange rate. There was a solid organic growth in Sweden underpinned by (i) primary care activity benefitting from additional volumes from light emergency centres taken over since January 2025 and increased remuneration for extended care responsibility assumed; (ii) growing volumes in St. Göran with a reduced length of stay, the continued ramp-up of its new maternity, and the contribution from the new St. Göran contract since January 2026 at improved terms; and (iii) sustained demand in our Swedish elderly care and orthopaedics clinics.

EBITDA

Ramsay Santé Group’s consolidated EBITDA has increased +€16.3m to €637.7m (or +2.6% year-on-year).

The Group’s EBITDA was driven by resilient organic volume growth, translating into sustainable operating performance through disciplined focus on productivity which more than compensated the end of the French government’s revenue guarantee from 1^st January 2025, representing a €20m shortfall vs. last year. Public funding otherwise received through revisions of French tariffs and various public payors in the Nordics still only partially covered inflation from medical staff salary and wages as well as overall procurement and outsourced services price increases, putting pressure on operating margins.

Productivity efforts and cost control across all geographies already initiated last year have been reinforced and were essential for the Group operations to offset cost inflation, grow EBITDA and maintain EBITDA margins at 11.9% (in line with last year, and higher than 11.5% last year excluding temporary French revenue guarantee) despite facing a challenging funding environment. The corresponding actions aim to (i) optimize operational costs utilisation to produce patient care services, (ii) adjust administrative overhead costs to align with the needs of the business and (iii) secure and develop revenue streams.

Productivity has been achieved by adapting staffing wherever possible, carefully adjusting hiring structure (e.g. agency staff), as well as optimizing medical purchases and consumption. Process enhancement improved coding accuracy and cash collection ensuring appropriate reimbursement for services provided, and further development in activities such as in day medicine and imaging expanded revenue streams. In addition, the facility network is regularly reviewed and optimized through consolidation, activity transfers (notably maternity) and rationalization to create a leaner and more agile platform.

Operating profit and non-current items

Underlying current operating profit amounted to €196.9m, up €9.5m year-on-year. The performance of the Group along with reduced capital expenditures compared to previous year has enabled to absorb increased rental costs mostly related to the half-year effect of the new St. Göran contract effective on 5^th January 2026.

Other non-current income and expenses represent a net expense of €(10.6)m for full year ending June 2026, (overall lower than last year level of €(14,2)m) and mainly comprise :

• A €8.9m net accounting gain on the sale and lease-back of 4 real estate assets in France (please refer to Significant events of the period)
• A €9.3m provision reversal consecutive to a favorable outcome in a VAT litigation in Sweden
• A €4.6m reversal of a one-off provision for annual leave in France raised in FY24 no longer required
• A €(4.2) non-cash impairment costs on one underperforming clinic in France consecutive to the review of the portfolio asset value as part of the full year close process
• €(15.6)m of various restructuring and write-off costs associated with the rationalization and reorganisation of activities in the Nordics and in France (in particular maternity transfers)
• €(12.7)m of transaction and development costs including €(5,7)m one-off costs associated with the demerger project contemplated by Ramsay Healthcare, as well as in the Nordics related to the implementation of a new EMR system in Norway and St. Göran new contract integration.

Financial result and net result after tax

The cost of net financial debt amounted to €191.2m, vs. €194.4m last year. The lower interest costs result from the decrease in the senior debt margin post February 2025 refinancing in this period, and old borrowing costs write-off in the prior period further to the February 2025 refinancing transaction, partly offset by accelerated write-off of residual borrowing costs on TLB senior debt done as of 30^th June 2026 incidental to the new refinancing closed on 22^nd July 2026 (please refer to Significant subsequent events since the period).

Other financial income and expenses amounted to €2.1m vs. €12.2m in June 2025 which included a €7.2m expense from non-cash mark to market movements on an interest rate swap hedging arrangement (this impact did not reoccur since as this particular swap instrument matured in October 2024).

Net result (Group’s share) amounted to €(48.3)m, improving €5.8m from last year’s net loss of €(54.1)m.

Restated aggregates:

Reported EBITDA of €637.7m (+€16.3m vs. last year) in accordance with IFRS16 excludes contracted operating or non-financial lease expenses for €287.9m (vs. €273.5m last year) which are instead recorded as amortisation of the right-of-use asset and interest on the lease debt. The table below shows restated P&L aggregates deriving from reported aggregates that have been restated from the IFRS16 impact on operating rents or non-financial rents (please refer to glossary for further details)

P&L aggregates restated from the IFRS16 impact on operating rents or non-financial rents (refer to glossary)

€ millions		June 30, 2026				June 30, 2025				Δ
		Reported	Restatement impact	Restated		Reported	Restatement impact	Restated		Restatement impact
EBITDA % of revenue		637.7	287.9	349.8		621.4	273.5	347.9		14.4
		11.9%		6.5%		11.9%		6.6%
Depreciation & amortisation		(440.8)	(228.2)	(212.6)		(434.0)	(217.4)	(216.6)		(10.8)
Current operating profit		196.9	59.7	137.2		187.4	56.1	131.3		3.6
Financial result		(193.4)	(76.3)	(117.1)		(206.6)	(74.8)	(131.8)		(1.5)
Net result		(33.3)	(23.1)	(10.2)		(38.1)	(11.4)	(26.7)		(11.7)

Cash-flow and financing

Compared to last year, the €(169)m decrease in operating cash flow, despite starting from a €16m higher EBITDA, mainly stems from a €(179)m change in working capital movement, due to (i) a €(133)m variation from French state advances as last fiscal year benefited from higher amount of French State cash advances (extended due to the late publication of tariffs) still to be repaid at year-end compared to previous year, while almost all state advance has been reimbursed as at 30^th June 2026, (ii) a €(74)m variation related to the implementation of new factoring scheme at the end of June 2025, which has now been renewed at a comparable level, (iii) slightly offset by improvements in debtors and creditors leading to positive working capital movements compared to last year.

Investment in tangible and intangible capital expenditure reached €143,9m for the year ending June 2026 in line with €142.8m last year. Capital expenditure included maintenance and optimization, as well as improvement on our portfolio of clinics and imaging equipment. The Group actively manages its portfolio of assets and where practical reallocates capital to its development priorities.

Disposal of tangible and intangible assets of the year includes €44.7m of net proceeds from the sale and leaseback of four properties (refer to significant events of the period).

Change in other financial assets includes the expected one-off €26m deposit payment incidental to the set-up of the new St. Göran contract.

The financing cash outflow of the period is improved by €96m compared to last year overall mainly through (i) new €34m debt drawn by refinancing the Mermoz real estate in France (€65m new mortgage loan less €31m lease acquisition option payment – refer to significant events of the period), and borrowing costs paid as part of last year’s refinancing and repricing as well as short term debt repayments not reoccurring this fiscal year.

Cash and cash equivalents amounted to €302.2m at the end of the year and reported IFRS net debt was €3,584.9m. Restated net debt amounts to €1,638.7m as of 30^th June 2026 down versus 30^th June 2025 (€1,675.9m).
Restated net leverage amounts to 4.7x as of June 2026, stable vs. 4.7x last year.

About Ramsay Santé

Ramsay Santé is the European leader in private hospitalisation and primary care. With 40,000 employees and 10,000 practitioners, the group welcomes 13 million patients each year in 492 facilities across five countries (France, Sweden, Norway, Denmark and Italy).

As a mission-driven company, Ramsay Santé covers the entire care pathways in medicine, surgery, obstetrics, medical and rehabilitation care, mental health and primary care centres, with constant innovation to improves everyone’s health and ensures equitable access to secure and qualitative care.

Facebook: https://www.facebook.com/RamsaySante 
Instagram: https://www.instagram.com/ramsaysante 
Twitter: https://twitter.com/RamsaySante 
LinkedIn: https://www.linkedin.com/company/ramsaysante 
YouTube: https://www.youtube.com/c/RamsaySante 

Code ISIN and Euronext Paris: FR0000044471 
Website:  www.ramsaysante.fr 

Investor / Analyst Relations        Press Relations

Clément Lafaix        Brigitte Cachon
Tél. +33 1 87 86 21 52        Tél. +33 1 87 86 22 11
clement.lafaix@ramsaysante.fr        brigitte.cachon@ramsaysante.fr

Summary of results

P&L – in € millions	From July 1, 2025 to June 30, 2026	From July 1, 2024 to June 30, 2025	Variation
Revenue	5,381.1	5,207.9(1)	+3.3%
EBITDA	637.7	621.4	2.6%
As a % of revenue	11.9%	11.9%	+0.0 pts
Current Operating Result	196.9	187.4	+5.1%
As a % of revenue	3.7%	3.6%	+0.1 pts
Operating Profit	186.3	173.2	+7.6%
As a % of revenue	3.5%	3.3%	+0.2 pts
Net result attributable to owners of the Company	(48.3)	(54.1)	+10.7%
Earnings per share (in €)	(0.44)	(0.49)	+10.2%

(1)   Adjusted of a reclassification of €-34.1m on revenue and +€34.1m on purchased consumables, with no impact on EBITDA.

Breakdown of revenue by operating segment

In € million	From July 1, 2025 to June 30, 2026	From July 1, 2024 to June 30, 2025	Variation
Île-de-France	1,347.7	1,327.5	+1.5%
Auvergne-Rhône-Alpes	690.7	683.4	+1.1%
Hauts de France	450.0	442.4	+1.7%
Occitanie	335.5	322.5	+4.0%
Other regions	845.1	824.2	+2.5%
Nordic countries	1,712.1	1,607.9	+6.5%
Reported Revenue	5,381.1	5,207.9	+3.3%

Note: The table above details the contributions of the various operating segments to the Group’s consolidated revenue.

Changes in revenue between 30^th June 2026 vs. the previous year in €m

Reported revenue June 30, 2025	Changes in FX rates	Acquisitions and disposals	Organic growth	Reported revenue June 30, 2026	Variation
5,207.9(1)	51.0	3.3	118.9	5,381.1	+173.2
	1.0%	0.1%	2.3%		+3.3%

^{(1) Adjusted of a reclassification of €-34.1m on revenue and +€34.1m on purchased consumables, with no impact on EBITDA.}

Net Financial Debt – in € millions	June 30,2026	June 30, 2025
Non-current borrowings and debt	1,854.6	1,841.2
Non-current lease debt (2)	1,849.0	1,890.5
Current lease debt (2)	259.4	268.7
Current borrowings and debt	68.2	61.0
(Cash and cash equivalents)	(302.2)	(366.5)
Other financial (assets) & liabilities	(144.1)	(47.4)
Net financial debt	3,584.9	3,647.5

(2) of which standard lease debt (€1,946.2m as of June 26 and €1,972.4m as of June 25) and financial lease debt (€162.2m as of June 26 and €186.8m as of June 25)

Cash Flow Statement – in € millions	From July 1, 2025 to June 30, 2026	From July 1, 2024 to June 30, 2025
EBITDA (a)	637.7	621.4
Changes in working capital (b)	(44.0)	135.4
Other items (c)	(69.0)	(63.1)
Net cash flow from operating activities (a)+(b)+(c)	524.7	693.7
Net cash flow from investing activities	(132.9)	(138.4)
Net cash flow from financing activities	(454.0)	(550.2)
Change in net cash position	(62.2)	5.1
FX translation differences on cash and cash equivalents	(2.1)	2.4
Opening cash and cash equivalents	366.5	359.0
Closing cash and cash equivalents	302.2	366.5

P&L lease restatement – in € millions	From July 1, 2025 to June 30, 2026	From July 1, 2024 to June 30, 2025
EBITDA reported	637,7	621,4
Restatement – Operating leases	(287,9)	(273,4)
EBITDA restated	349,8	347,9

Cash-flow lease payments – in € millions	From July 1, 2025 to June 30, 2026	From July 1, 2024 to June 30, 2025
Operating leases	(287,9)	(273,4)
Financial leases	(54,4)	(58,7)
Repayment of Mermoz financial lease option	(31,0)	n.a.
Other	1,0	0,4
Total lease payments	(372,3)	(331,7)
o/w Financial interest related to lease liability (IFRS16)	(81,6)	(80,1)
o/w Decrease in lease liability (IFRS16)	(290,6)	(251,6)

Glossary

• Constant perimeter, or like-for-like comparison
  • The cancelation of incoming entities consists in:
    • for entries in the current year’s scope, deducting the contribution of the acquisition on the current year’s aggregates;
    • for entries in the previous year’s scope, deducting in the current year’s aggregates, the contribution of the acquisition prior to the month of acquisition.
  • The cancelation of outgoing entities consists in:
    • for exits in the current year’s scope, deducting in the previous year’s aggregates, the contribution of the exiting entity from the month of exit;
    • for exits in the previous year, deducting the contribution of the exiting entity for the entire previous year’s aggregates.
• The change at constant exchange rates reflects a change after translation of the current period’s foreign currency figure at the exchange rates of the comparative period.
• The change on a constant accounting basis reflects a change in the figure excluding the impact of changes in accounting standards during the period.
• Current operating profit refers to operating profit before other non-recurring income and expenses consisting of restructuring costs (charges and provisions), gains or losses on disposals or significant and unusual impairments of non-current assets, whether tangible or intangible, and other unusual operational income and expenses.
• EBITDA corresponds to current operating profit before depreciation (expenses and provisions in the income statement are grouped according to their nature).
• Net financial debt is gross financial debt less financial assets.
  • The gross financial debts are made up of:
    • borrowings from credit institutions, including interest incurred;
    • lease liabilities falling within the scope of IFRS 16;
    • fair value of hedging instruments recorded in the balance sheet, net of tax;
    • current financial debt relating to financial current accounts with minority investors;
    • bank overdrafts.
  • Financial assets consist of:
    • the fair value of hedging instruments recorded in the balance sheet, net of tax;
    • current financial receivables relating to financial current accounts with minority investors;
    • Cash and cash equivalents, including treasury shares held by the Group (considered as marketable securities);
    • financial assets directly related to the loans contracted and recognized in gross financial debt.

• Restated aggregates are calculated based on reported aggregates that have been restated from the IFRS16 impact on operating rents or non-financial rents (but not from the IFRS16 impact on leasing and lease financing that is still included). As an illustration:
  • Restated EBITDA includes operating rents or non-financial rents (as compared with reported EBITDA)
  • Restated Net Debt does not include current and non-current lease debt linked to operating rents or non-financial rents (as compared with the reported Net Debt)
  • Restated net leverage ratio derives from restated Net Debt and restated LTM EBITDA

Annual financial results as of June 30, 2026

CONSOLIDATED INCOME STATEMENT
(In millions of euros)	From July 1, 2025 to June 30, 2026	From July 1, 2024 to June 30, 2025
REVENUE	5,381.1	5,207.9(1)
Personnel costs	(2,735.3)	(2,655.9)
Purchased consumables	(1,150.7)	(1,124.0) (1)
Other operating income and expenses	(631.6)	(570.7)
Taxes and duties	(142.5)	(148.5)
Rents	(83.3)	(87.4)
EBITDA	637.7	621.4
Depreciation and amortisation	(440.8)	(434.0)
Current operating profit	196.9	187.4
Other non-recurring income and expenses	(10.6)	(14.2)
Operating profit	186.3	173.2
Finance costs on gross debt	(112.8)	(119.0)
Income from cash and cash equivalents	3.2	4.7
Financial interests related to the lease debt (IFRS16)	(81.6)	(80.1)
Finance costs on net debt	(191.2)	(194.4)
Other financial income	4.7	3.5
Other financial expenses	(6.8)	(15.7)
Other financial income and expenses	(2.1)	(12.2)
Income tax	(19.5)	(1.6)
Net result from discontinued operations	(6.8)	(3.1)
CONSOLIDATED NET RESULT	(33.3)	(38.1)
– Net result attributable to owners of the Company	(48.3)	(54.1)
– Non-controlling interests	15.0	16.0
NET RESULT PER SHARE (in euros)	(0.44)	(0.49)
DILUTED NET RESULT PER SHARE (in euros)	(0.44)	(0.49)

(1)   ^{Adjusted of a reclassification of €–34.1m on revenue and +€34.1m on purchased consumables, with no impact on EBITDA.}

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(In millions of euros)	From July 1, 2025 to June 30, 2026		From July 1, 2024 to June 30, 2025
CONSOLIDATED NET RESULT	(33.3)		(38.1)
Foreign exchange translation differences	1.1		9.5
Cash flow hedges	14.1		(9.9)
Items that may be reclassified to Profit & Loss	15.2		(0.4)
Actuarial gains and losses relating to post-employment benefits	6.3		4.9
Other	2.3		0.5
Items that may not be reclassified to Profit & Loss	8.6		5.4
Other comprehensive income after tax	23.8		5.0
CONSOLIDATED COMPREHENSIVE INCOME	(9.5)		(33.1)
– Comprehensive income attributable to owners of the Company	(24.5)		(49.1)
– Non-controlling interests	15.0		16.0
CONSOLIDATED BALANCE SHEET – ASSETS
(In millions of euros)		30/06/2026		30/06/2025
Goodwill		2,063.4		2,087.9
Other intangible assets		210.2		205.5
Property. plant and equipment		931.2		936.0
Right of use assets (IFRS16)		1,904.4		2,028.2
Investments accounted for the equity method		0.2		0.2
Non-current financial assets		255.2		160.0
Deferred tax assets		127.6		114.7
NON-CURRENT ASSETS		5,492.2		5,532.5
Inventories		131.3		125.1
Trade and other operating receivables		470.9		527.5
Other current assets		269.2		260.7
Current tax assets		7.3		6.3
Current financial assets		8.9		17.5
Cash and cash equivalents		302.2		366.5
CURRENT ASSETS		1,189.8		1,303.6
ASSETS HELD FOR SALE		0.0		2.9
TOTAL ASSETS		6,682.1		6,839.0

CONSOLIDATED BALANCE SHEET – EQUITY AND LIABILITIES
(In millions of euros)	30/06/2026	30/06/2025
Share capital	82.7	82.7
Share premium	611.2	611.2
Consolidated reserves	475.1	505.4
Net income attributable to owners of the Company	(48.3)	(54.1)
Equity attributable to owners of the Company	1,120.7	1,145.2
Non-controlling interests	35.1	36.6
TOTAL EQUITY	1,155.8	1,181.8
Borrowings and debt	1,854.6	1,841.2
Debt on commitment to purchase minority interests	13.3	16.9
Non-current lease debt (IFRS16)	1,849.0	1,890.5
Provisions for post-employment benefits	100.9	102.9
Non-current provisions	137.9	139.4
Other non-current liabilities	6.3	16.2
Deferred tax liabilities	38.4	29.4
NON-CURRENT LIABILITIES	4,000.4	4,036.5
Current provisions	26.6	33.6
Trade and other accounts payable	427.7	432.3
Other current liabilities	721.3	811.1
Current tax liabilities	13.2	5.4
Current financial debts	68.2	61.0
Debt on commitment to purchase minority interests	9.5	5.3
Current lease debt (IFRS16)	259.4	268.7
CURRENT LIABILITIES	1,525.9	1,617.4
LIABILITIES RELATED TO ASSETS HELD FOR SALE	0.0	3.3
TOTAL EQUITY AND LIABILITIES	6,682.1	6,839.0

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
(In millions of euros)	SHARE CAPITAL	SHARE PREMIUM	RESERVES	RESULTS DIRECTLY RECORDED IN EQUITY	NET INCOME ATTRIBUTABLE TO OWNERS OF THE COMPANY	EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY	NON-CONTROLLING INTEREST	EQUITY
At June 30, 2024	82.7	611.2	615.6	(61.3)	(53.9)	1,194.3	35.4	1,229.7
Capital increase (after deduction of issue costs net of tax)	—	—	—	—	—	—	—	—
Treasury shares	—	—	—	—	—	—	—	—
Stock options and free shares	—	—	—	—	—	—	—	—
Prior year result to be allocated	—	—	(53.9)	—	53.9	—	—	—
Dividend distribution	—	—	—	—	—	—	(14.4)	(14.4)
Change in scope of consolidation	—	—	—	—	—	—	(0.4)	(0.4)
Total comprehensive income for the year	—	—	—	5.0	(54.1)	(49.1)	16.0	(33.1)
At June 30, 2025	82.7	611.2	561.7	(56.3)	(54.1)	1,145.2	36.6	1,181.8

At June 30, 2025	82.7	611.2	561.7	(56.3)	(54.1)	1,145.2	36.6	1,181.8
Capital increase (after deduction of issue costs net of tax)	—	—	—	—	—	—	—	—
Treasury shares	—	—	—	—	—	—	—	—
Stock options and free shares	—	—	—	—	—	—	—	—
Prior year result to be allocated	—	—	(54.1)	—	54.1	—	—	—
Dividend distribution	—	—	—	—	—	—	(16.5)	(16.5)
Change in scope of consolidation	—	—	—	—	—	—	—	—
Total comprehensive income for the year	—	—	—	23.8	(48.3)	(24.5)	15.0	(9.5)
At June 30, 2026	82.7	611.2	507.6	(32.5)	(48.3)	1,120.7	35.1	1,155.8

CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions of euros)	From July 1, 2025 to June 30, 2026	From July 1, 2024 to June 30, 2025
Net result of the consolidated group	(33.3)	(38.1)
Depreciation and amortisation	440.8	434.0
Other non-current income and expenses	10.6	14.2
Share of net result of associates	—	—
Other financial income and expenses	2.1	12.2
Financial interest related to the lease liability (IFRS16)	81.6	80.1
Cost of net financial debt excluding financial interest related to lease liability	109.6	114.3
Income tax	19.5	1.6
Net income from discontinued operations	6.8	3.1
EBITDA	637.7	621.4
Non-cash items relating to recognition and reversal of provisions (non-cash transactions)	(8.2)	(4.2)
Other non-current income and expenses paid	(17.4)	(16.5)
Change in other non-current assets and liabilities	(18.5)	(22.7)
Cash flow from operations before cost of net financial debt and tax	593.6	578.0
Income tax paid	(21.3)	(17.9)
Change in working capital	(44.0)	135.4
Impact of discontinued operations on operating activities	(3.6)	(1.8)
NET CASH FLOWS FROM OPERATING ACTIVITIES: (A)	524.7	693.7
Investment in tangible and intangible assets	(143.9)	(142.8)
Disposal of tangible and intangible assets	50.3	7.0
Acquisition of entities	(2.7)	(5.1)
Disposal of entities	(1.6)	1.3
Change in other financial assets	(32.5)	—
Dividends received from non-consolidated companies	0.9	1.6
Impact of discontinued operations on investing activities	(3.4)	(0.4)
NET CASH FLOW FROM INVESTING ACTIVITIES: (B)	(132.9)	(138.4)
Capital increase and share premium increases: (a)	—	—
Capital increase of subsidiaries subscribed by third parties: (b)	—	—
Dividends paid to minority shareholders of consolidated companies: (c)	(16.5)	(14.4)
Interest paid: (d)	(104.5)	(108.5)
Financial income received and other financial expenses paid: (e)	1.6	1.5
Financial interest related to lease liability (IFRS16): (f)	(81.6)	(80.1)
Debt issue costs: (g)	(1.0)	(14.2)
Cash flow before change in borrowings: (h) = (A+B+a+b+c+d+e+f+g)	189.8	339.6
Increase in borrowings: (i)	76.3	63.1
Repayment of borrowings: (j)	(45.4)	(148.2)
Decrease in lease liability (IFRS16): (k)	(290.6)	(251.6)
Impact of discontinued operations on financing activities: (l)	7.7	2.2
NET CASH FLOW FROM FINANCING ACTIVITIES: (C) = a + b + c + d + e + f + g + i + j + k + l	(454.0)	(550.2)
NET INCREASE IN CASH AND CASH EQUIVALENTS: ( A + B + C )	(62.2)	5.1
Foreign exchange translation differences on cash and cash equivalents held	(2.1)	2.4
Cash and cash equivalents at beginning of year	366.5	359.0
Cash and cash equivalents at end of year	302.2	366.5

---

1 Excluding FX effect
2 CAGR FY2026-2029
3 Based on latest known tax framework (refer to page 4)

Attachment

• RAMSAY SANTE – Final results as of 30 June 2026

ALBION TECHNOLOGY & GENERAL VCT PLC

LEI Code 213800TKJUY376H3KN16

TRANSACTION IN OWN SHARES AND TOTAL VOTING RIGHTS AND CAPITAL

Albion Technology & General VCT PLC (the “Company”) announces that it purchased 3,624,517 ordinary shares at 63.17 pence per share on 6 October 2026. The shares purchased represent 0.89% of the total number of voting rights in the Company before the transaction.  These shares will be cancelled.

Following the above transaction, and in accordance with the FCA’s Disclosure Guidance and Transparency Rules, the capital of the Company as at close of business on 6 October 2026 consisted of 437,899,850 ordinary shares with a nominal value of 1 penny each. The Company holds 32,370,947 ordinary shares in treasury.

Therefore, the total number of voting rights in the Company is 405,528,903.  These figures may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in or a change to the interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

6 October 2026

Vikash Hansrani
Operations Partner
AlbionVC LLP
Tel: 020 7601 1850

First Patient Dosed with JOTROL^™ Marks Major Clinical Milestone for Jupiter Neurosciences’
Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL^™ in Patients with Parkinson’s Disease

Tungsten Advisors has been retained to identify strategic options to monetize Jupiter’s existing clinical development programs via corporate partners and explore other strategic options for a transaction to maximize shareholder value

Jupiter, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that the first patient has been dosed in the company’s Phase 2a RESET clinical trial evaluating JOTROL^™ in patients with Parkinson’s disease (PD).

The dosing of the first patient represents an important clinical milestone for Jupiter and marks the transition of JOTROL^™ into Phase 2a clinical evaluation in patients with Parkinson’s disease. The RESET study (NCT07592767) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and biomarker effects of JOTROL^™, Jupiter’s investigational, proprietary micellar formulation of trans-resveratrol.

“Dosing the first patient in RESET is a significant milestone for Jupiter and the culmination of years of scientific, regulatory and clinical development work,” said Christer Rosén, Chief Executive Officer of Jupiter Neurosciences. “We believe that JOTROL has the potential to address biological pathways implicated in Parkinson’s disease, including mitochondrial dysfunction, oxidative stress and neuroinflammation. With patient dosing now underway, we look forward to advancing enrollment and generating clinical data that will help us evaluate JOTROL’s potential in this significant area of unmet medical need.”

RESET is expected to enroll approximately 30 patients with Parkinson’s disease who will be randomized 1:1:1 to receive one of two dose levels of JOTROL^™ or placebo. Study treatment will be administered orally for 12 weeks. The trial’s primary objectives include assessment of safety, tolerability and pharmacokinetics, including evaluation of JOTROL^™ exposure in plasma and cerebrospinal fluid. Secondary and exploratory assessments include biomarkers associated with energy metabolism, inflammation and Parkinson’s disease, as well as clinical outcome measures.

“The first patient dosed in RESET represents an important step in translating the scientific rationale for JOTROL into a clinical study in people living with Parkinson’s disease,” said the study’s principal investigator Fernando L. Pagan, MD, professor of neurology at Georgetown University School of Medicine and Vice Chairman of the Department of Neurology. Georgetown University is the study sponsor. “This study is designed to provide important information regarding JOTROL’s safety, pharmacokinetics and biological activity in Parkinson’s disease and to help inform the future clinical development of the program.”

JOTROL^™ is designed to overcome limitations associated with the bioavailability of conventional resveratrol. In a completed Phase 1 study in healthy volunteers, JOTROL^™ demonstrated increased systemic exposure to resveratrol and measurable cerebrospinal fluid concentrations. The Phase 1 study reported no serious adverse events. Preclinical studies in a model of Parkinson’s disease also demonstrated neuroprotective effects, including improvements in measures of motor function. These findings supported advancement of JOTROL^™ into the RESET Phase 2a study.

“Moving from enrollment to dosing our first patient is a defining moment for Jupiter and, importantly, puts us in a position to begin generating patient data from our lead clinical program,” said Alison Silva, President and Chief Business Officer of Jupiter Neurosciences. “We are grateful to the patients, investigators, clinical sites and collaborators participating in RESET. We remain focused on efficient execution of the study and look forward to providing updates as the program progresses.”

As the company continues to enroll patients in the RESET trial, it has also initiated a formal process to explore and evaluate strategic options to maximize shareholder value. These options may include the sale or licensing of clinical and other assets, strategic partnerships, business combinations, or other corporate transactions.

Jupiter has engaged Tungsten Advisors as the company’s strategic advisor. There can be no assurance that this process will result in any transaction. Jupiter does not intend to provide updates regarding the process unless and until its Board of Directors approves a specific transaction or the Company otherwise determines that disclosure is appropriate or required.

About Parkinson’s Disease Market

• 1.1 million U.S. patients living with Parkinson’s Disease https://www.parkinson.org/understanding-parkinsons/statistics
• 90,000 new U.S. diagnoses annually; 1.2 million U.S. patients projected by 2030 https://www.parkinson.org/understanding-parkinsons/statistics
• $82.2 billion annual U.S. economic burden of Parkinson’s Disease https://www.parkinson.org/understanding-parkinsons/statistics
• ~90% of PD patients are Medicare-enrolled https://data.cms.gov/summary-statistics-on-beneficiary-enrollment
• No disease-modifying therapies currently approved for PD; multiple investigational candidates are in active development by other companies https://www.accessdata.fda.gov/scripts/cder/daf
• Global PD treatment market: $5.65B (2024) → $7.58B (2030), CAGR 5.04% https://www.grandviewresearch.com/industry-analysis/parkinsons-disease-drugs-market
• Global prevalence: >10 million patients https://doi.org/10.1016/S1474-4422(18)30295-3

About the RESET Trial

RESET (RESvEraTrol in Parkinson’s Disease) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating JOTROL^™ in approximately 30 patients with Parkinson’s disease. Participants are randomized to receive one of two doses of JOTROL^™ or placebo over a 12-week treatment period.

The study is designed primarily to evaluate safety, tolerability and pharmacokinetics and will also examine pharmacodynamic and disease-relevant biomarkers, including measures associated with mitochondrial function, energy metabolism and inflammation. Exploratory clinical assessments are intended to provide additional information to inform the design of future JOTROL^™ clinical studies. Additional information regarding RESET is available at ClinicalTrials.gov under identifier NCT07592767. Dr. Charbel Moussa, a sub-investigator on this study at Georgetown University, has financial interests related to Jupiter Neurosciences. 

About JOTROL^™

JOTROL^™ is Jupiter Neurosciences’ proprietary and patented micellar formulation of trans-resveratrol designed to improve the bioavailability of resveratrol. Resveratrol has been extensively studied for its potential effects on biological pathways associated with oxidative stress, inflammation and mitochondrial function. Jupiter is developing JOTROL^™ as an investigational therapeutic candidate for neurodegenerative and rare diseases.

JOTROL^™ is an investigational drug candidate and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Its safety and efficacy for the treatment of Parkinson’s disease or any other disease have not been established.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company’s lead program, JOTROL^TM – a proprietary, enhanced bioavailability resveratrol formulation – is currently in a Phase 2a clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia^TM, a consumer longevity supplement. Additionally, the Company’s pipeline includes ALA-002, a next-generation, patented psychedelic new chemical entity (NCE) recently in-licensed from PharmAla Biotech Holdings. For more information, please visit www.jupiterneurosciences.com.

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, without limitation, statements regarding the company’s pursuit of strategic options; patient enrolment and dosing timelines for the Phase 2a RESET trial; expected study completion dates; expected development timelines; and potential regulatory pathways. These forward-looking statements are often indicated by terms such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “should,” “slate,” “target,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, that clinical trials may not demonstrate adequate safety or tolerability; enrolment may be slower than anticipated; preliminary data may not be predictive of future results; the company’s inability to identify or consummate strategic opportunities on the terms contemplated or at all; and other risks, uncertainties and other factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed on April 1, 2026 and any subsequent quarterly reports. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements. We assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.com

CHIHUAHUA, Mexico, Oct. 06, 2026 (GLOBE NEWSWIRE) — GCC, S.A.B. de C.V. (BMV: GCC*), cement, aggregates and concrete in the United States and Mexico, will host a conference call to review its third quarter 2026 earnings results on Wednesday, October 28 at 11:00 a.m. (ET). Earnings results for the quarter ended September 30, 2026, will be released on Tuesday, October 27, after market close.

The call will be hosted by Enrique Escalante, CEO, and Maik Strecker, CFO, and can be accessed by dialing +1 (877) 407 0789 or +1 (201) 689 8562 for international calls. The conference ID is 13757650.

The presentation and listen-only webcast will be available via the following link.

A replay of the webcast will be available the same day at 2:00 p.m. (ET) until November 4 at 11:59 p.m. (ET). The replay can be accessed through this link or by dialing +1 (844) 512 2921 or +1 (412) 317 6671 for international calls. The replay PIN is 13757650. Additionally, an online replay of the live broadcast will be available on the Company’s website two days later.

For more information visit www.gcc.com or contact:

GCC Investor Relations
Sahory Ogushi
MX +52 (614) 442 3176
US + 1 (303) 739 5943
soguship@gcc.com

About GCC

GCC is a leading supplier and producer of cement, aggregates, concrete and construction‐related services in the United States and Mexico, with an annual cement production capacity of 7 million metric tons. Founded in 1941, the Company’s shares are listed on the Mexican Stock Exchange under the ticker symbol GCC*.

Consolidated harvest volumes:

	Q3 2026
Farming Central Norway	51.4
Farming Northern Norway	48.5
SalMar Ocean	0
Icelandic Salmon	5.2
Totalt	105.1

All figures in 1,000 tons gutted weight. 

Harvest volumes in Central Norway were affected towards the end of the quarter by harvesting due to ISA and fish welfare considerations, which impacted cost development during the period.

The full Q3 2026 report will be released on Tuesday 3 November 2026 at 06:30 CET, the following presentation will be available through Norwegian webcast at 08:00 CET and English webcast (recording) at 10:00 CET.

For more information, please contact:
Håkon Husby
Head of IR
Tel: +47 936 30 449
Email: hakon.husby@salmar.no

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act

Vancouver, BC, Canada, Oct. 06, 2026 (GLOBE NEWSWIRE) — Bear Gold Corp. (TSXV: BEAR) (the “Company” or “BEAR”) announces that its common shares are expected to resume trading on the TSX Venture Exchange (the “TSXV”) at market open on Thursday, October 8, 2026.

Trading in the Company’s common shares was halted on September 28, 2026, pending the announcement of the Company’s acquisition of an optioned interest in the Peerless Property.  As announced, the Company has entered into an assignment and assumption of property option agreement dated September 25, 2026, with Bathurst Metals Corp. (“BMV”) and Stanley R McClay as bare trustee for BCT Holdings Corp., pursuant to which the Company will acquire BMV’s 100% optioned interest in the Peerless Property located in the Bridge River Mining Camp, British Columbia.  This transaction is subject to TSXV approval.

Full details of the transaction are set out in the Company’s news release dated October 1, 2026.

About Big Bear Gold Corp.

Big Bear Gold Corp. is focused on acquiring and developing mineral properties with strong potential to host significant resources in Western Canada. We are looking for additional projects that are in an established mining district with highly prospective geology that could host significant resources.

ON BEHALF OF THE BOARD OF DIRECTORS
“Peter Laipnieks”
Peter Laipnieks, President & CEO

Contacts:
Big Bear Gold Corp.
Suite 900, 570 Granville Street
Vancouver, BC  V6C 3P1

Investor Relations: (250) 216.5674
Email:  bigbeargold007@gmail.com
Website: bigbeargold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information
All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements.  Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management.  These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances.  In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control.  Actual events or results may differ materially from those projected in the forward-looking statements and the Company cautions against placing undue reliance thereon. 

The Company believes that the expectations reflected in forward-looking statements included herein are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein should not be unduly relied upon.  These statements speak only as of the date hereof.  The Company does not intend, and does not assume any obligation, to revise or update these forward-looking statements, except as required by applicable law.

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that LaFleur Minerals Inc. have reported drill results from the Bartec portion of the Swanson Property in Barraute Township, Quebec upon which Globex retains a two percent (2%) Gross Metal Royalty (GMR).

Hole SW-26-124 returned 6.05 g/t Au over 8m (26.2ft) including 14.96 g/t Au over 3.0 m (9.8 ft) from in-hole depths of 38.0 m to 46.0 m.   True width has yet to be determined as this is the first modern-day drill hole in the gold occurrence.

Shareholders can access the Lafleur press release by clicking here.

Sampling, QAQC, and Laboratory Analysis Summary

All core logging and sampling completed by LaFleur Minerals as part of its diamond drilling program was subject to a strict standard for Quality Control and Quality Assurance (QAQC), which included the insertion of certified reference material (standards), blank materials, and field duplicate analysis. NQ-diameter sawed half-core samples from the drilling program at Bartec were securely sent by Company geologists to AGAT Laboratories Ltd. (AGAT), with sample preparation in Val-d’Or, Québec and analysis in Thunder Bay, Ontario,

The LaFleur Qualified Person notes no drilling, sampling or recovery factors that could materially affect the accuracy or reliability of the data.

Jack Stoch, P.Geo., Executive Chairman and CEO of Globex, in his capacity as a Qualified Person (Q.P.) under Ni 43-101, prepared the information that forms the basis of this written disclosure.

We Seek Safe Harbour.	Foreign Private Issuer 12g3 – 2(b)
	CUSIP Number 379900 50 9 LEI 529900XYUKGG3LF9PY95
For further information, contact:
Jack Stoch, P.Geo., Acc.Dir. Executive Chairman & CEO Globex Mining Enterprises Inc. 120 Carlton Street, Unit 219 Toronto, Ontario, Canada M5A 4K2	Tel.: 819.797.5242 Fax: 819.797.1470 info@globexmining.com www.globexmining.com

Caution Regarding Forward-Looking Statements

Certain statements included in this press release may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. Except as may be required by such laws, Globex Mining Enterprises Inc. (“Globex”) does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements, by their very nature, are subject to numerous risks and uncertainties. As a result, actual results could differ materially from Globex’s expectations expressed in or implied by such forward-looking statements. No assurance can be given that any events anticipated by the forward-looking statements will materialize, or if any of them do, what benefits Globex will derive therefrom. Numerous risk factors which may cause actual results to differ materially from expectations expressed in or implied by the forward-looking statements are discussed in Globex’s annual information form for the 2025 fiscal year filed with the Canadian securities regulatory authorities, available on SEDAR+ at www.sedarplus.ca and on Globex’s website at www.globexmining.com. Globex cautions readers that such risks are not the only ones that could impact it. Additional risks and uncertainties not currently known to Globex or that Globex currently deems to be immaterial may have a material adverse effect on Globex’s business, financial condition, and results of operations. Given these risks and uncertainties, Globex cautions investors and others against placing undue reliance on such forward-looking statements as a prediction of future results or for any other purpose. This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “1933 Act”), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the 1933 Act), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the 1933 Act.

BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.

During the Period, 3,218,333 stock warrants were exercised for gross proceeds of $1,287,333.

During the Period, the following stock warrants have expired.

Number of warrants	Issue date	Original expiry date	Amended expiry date
1,414,286	February 27, 2024	August 27, 2025	August 5, 2026
650,000	March 22, 2024	September 22, 2025	August 5, 2026
1,125,000	May 9, 2024	November 9, 2025	August 5, 2026
3,502,931	June 5, 2024	December 5, 2025	August 5, 2026
8,333,333	September 20, 2024	March 20, 2026	September 5, 2026
2,655,691	October 25, 2024	April 25, 2026	September 25, 2026

As at the date of this press release, the following stock warrants are outstanding and can be exercised at the price of $0.40 per common share.

Number of warrants	Issue date	Original expiry date	Amended expiry date
6,715,369	February 5, 2025	August 5, 2026	June 5, 2027
13,494,459	December 5, 2025	June 5, 2027	n/a
513,248	December 5, 2025	June 5, 2027	n/a

DIAGNOS would like to thank the shareholders for their continuous support.

The currency stated in this press release is the Canadian dollar.

About DIAGNOS
DIAGNOS is a public Canadian corporation dedicated to the early detection of critical eye-related health problems. DIAGNOS manufactures CARA System, a software platform which assists health specialists in the detection of retinal eye pathologies. CARA System is currently licensed for commercialization in Canada and Saudi Arabia. By developing innovative products based on AI technologies, DIAGNOS’ solutions provide healthcare clinicians with valuable information that refines diagnostic accuracy, streamlines workflows, and improves patient outcomes.

Additional information is available at www.diagnos.com and www.sedarplus.com.

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	easyJet plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	05/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	27 2/7p ordinary (ISIN-GB00B7KR2P84)
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	16,772,528	2.21%
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	16,535,013	2.21%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
27 2/7p ordinary	CFD	Increasing a long position	236,891	GBP 6.7600
27 2/7p ordinary	CFD	Increasing a long position	624	GBP 6.7615

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	06/10/2026
Contact name:	Alex McMillan
Telephone number:	646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Viridien

A French société anonyme
with a share capital of € 7,219,747
Registered office: 27 avenue Carnot, 91300 Massy, France
Evry Trade and Companies Register 969 202 241

Information on the total number of voting rights and shares

Pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial markets authority
(AMF- Autorité des Marchés Financiers)

Date of the information	Total number of issued shares	Number of actual voting rights*	Number of theoretical voting rights**
September 30, 2026	7,219,747	7,255,970	7,256,219

*         All of the Company shares have the same voting rights, except for treasury shares which do not have voting rights and registered shares held for more than two years, which have double voting rights.

**         Pursuant to Article 223-11 of the General Regulation of the French Financial markets authority, the number of theoretical voting rights is calculated based on the shares having either single or double voting rights, including treasury shares which are deprived of voting rights.

Attachment

• 2026.09.30_information mensuelle AMF ENG